Status:
COMPLETED
CP1150 Sound Processor Speech Perception Compared With the Next Generation of Signal Processing Technology
Lead Sponsor:
Cochlear
Collaborating Sponsors:
Avania
Conditions:
Hearing Impairment, Sensorineural
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical study aims to investigate speech performance in quiet with an OTE Sound Processor with modified firmware compared with the commercially available CP1150. The study also investigates CP11...
Detailed Description
This study will build on the evidence previously collected on OTE and BTE Sound Processors and will support the design goals for access to the same sound processing algorithms across future OTE and BT...
Eligibility Criteria
Inclusion
- Aged 18 years or older
- Post lingually deafened
- Implanted with the CI600 Series, CI500 Series or Freedom Series
- At least 6 months experience with a cochlear implant.
- At least 3 months experience with a CP910/920, CP950, CP1150, or CP1000 Sound Processor
- MAP Total Stimulation Rate of 7.2kHz or greater
- Able to score 30% or more with CI alone on a monosyllabic words in quiet test
- Willingness to participate in and to comply with all requirements of the protocol
- Fluent speaker in English as determined by the investigator
- Willing and able to provide written informed consent
Exclusion
- Additional disabilities that would prevent participation in evaluations.
- Implant location that would result in undesirable hearing performance or discomfort with an off-the-ear sound processor, as determined by the investigator.
- Unable or unwilling to comply with the requirements of the clinical investigation, as determined by the Investigator.
- Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
- Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
- Currently participating or participated in another interventional clinical study/trial in the past 30 days unless (if less than 30 days) the prior investigation was Cochlear sponsored and determined by the investigator to not impact clinical findings of this investigation.
- Implanted with other active implantable medical devices (e.g. pacemaker, defibrillator).
Key Trial Info
Start Date :
May 30 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2022
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT05286385
Start Date
May 30 2022
End Date
June 29 2022
Last Update
February 7 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cochlear Sydney
Macquarie Park, New South Wales, Australia, 2109